Form 4: Cardiff Oncology Director Acquires Significant Stock Option Grant

Cardiff Oncology, Inc. Director Renee P. Tannenbaum acquired 40,565 stock options with an exercise price of $3.16 per share, signaling increased beneficial ownership.

Summary

• Renee P. Tannenbaum, a Director of Cardiff Oncology, Inc., acquired 40,565 stock options.
• The stock options have an exercise price of $3.16 per share.
• The transaction occurred on June 26, 2025.
• The acquired options become exercisable on June 26, 2026, and are set to expire on June 26, 2035.
• Following this transaction, Ms. Tannenbaum beneficially owns a total of 168,766 derivative securities, specifically stock options.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally viewed as a positive signal of confidence in the company's future prospects, although it is a routine insider transaction filing rather than a major operational or financial announcement.

Positives

• Director Renee P. Tannenbaum increased her beneficial ownership in Cardiff Oncology, Inc. by acquiring 40,565 stock options.
• The acquisition of stock options by a director can be interpreted as a positive signal of confidence in the company's long-term prospects and future performance.

Future Outlook

The stock options acquired by Director Renee P. Tannenbaum have an exercisable date of June 26, 2026, and an expiration date of June 26, 2035, indicating a long-term incentive structure and potential alignment with the company's future growth.

Industry Context

This filing is a routine regulatory disclosure for insider transactions, common across all publicly traded companies, reflecting changes in beneficial ownership by directors or officers.

Stakeholder Impact

• Shareholders may view the director's increased beneficial ownership as a positive indicator of management's confidence in the company's future, potentially influencing investor sentiment.

Next Steps

• The acquired stock options will become exercisable on June 26, 2026.

Key Dates

Keywords

Cardiff Oncology, CRDF, Stock Options, Director, Beneficial Ownership, Insider Transaction, Equity Compensation, SEC Form 4